Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203219 | 0.84 | HSD17B10 (0.56) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL17069049 | 0.84 | HSD17B10 (0.56) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL8222080 | 0.81 | HSD17B10 (0.59) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL30772231 | 0.80 | HSD17B10 (0.60) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL21163680 | 0.80 | HSD17B10 (0.51) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL20187282 | 0.79 | ACE (0.38) | HSD17B10LMNA | |
| SCHEMBL28133679 | 0.79 | HSD17B10 (0.62) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL4070752 | 0.77 | HSD17B10 (0.61) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL19414808 | 0.77 | HSD17B10 (0.61) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL5423413 | 0.77 | HSD17B10 (0.61) | HSD17B10UCHL1SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234638-B | Heteroaryl phenoxy benzamide KAPPA opioid ligands | 辉瑞大药厂 | 2022-10-21 | — | — | CN | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| EP-1786806-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | HSD17B10 1536/4885UCHL1 652/4885SMN1; SMN2 4238/4885 |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | HSD17B10 2705/4885UCHL1 486/4885SMN1; SMN2 1454/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | HSD17B10 2705/4885UCHL1 486/4885SMN1; SMN2 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.